170 related articles for article (PubMed ID: 20583973)
1. Molecular targeting of aberrant transcription factors in leukemia: strategies for RUNX1/ETO.
Wichmann C; Grez M; Lausen J
Curr Drug Targets; 2010 Sep; 11(9):1181-91. PubMed ID: 20583973
[TBL] [Abstract][Full Text] [Related]
2. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
[TBL] [Abstract][Full Text] [Related]
3. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.
Ptasinska A; Assi SA; Mannari D; James SR; Williamson D; Dunne J; Hoogenkamp M; Wu M; Care M; McNeill H; Cauchy P; Cullen M; Tooze RM; Tenen DG; Young BD; Cockerill PN; Westhead DR; Heidenreich O; Bonifer C
Leukemia; 2012 Aug; 26(8):1829-41. PubMed ID: 22343733
[TBL] [Abstract][Full Text] [Related]
4. Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins.
Barseguian K; Lutterbach B; Hiebert SW; Nickerson J; Lian JB; Stein JL; van Wijnen AJ; Stein GS
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15434-9. PubMed ID: 12427969
[TBL] [Abstract][Full Text] [Related]
5. NHR4 domain mutations of ETO are probably very infrequent in AML1-ETO positive myeloid leukemia cells.
Hackanson B; Abdelkarim M; Jansen JH; Lübbert M
Leukemia; 2010 Apr; 24(4):860-1. PubMed ID: 20090777
[No Abstract] [Full Text] [Related]
6. RUNX1-ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development.
DeKelver RC; Lewin B; Weng S; Yan M; Biggs J; Zhang DE
Leuk Lymphoma; 2014 Apr; 55(4):884-91. PubMed ID: 23772668
[TBL] [Abstract][Full Text] [Related]
7. RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis.
Yan M; Ahn EY; Hiebert SW; Zhang DE
Blood; 2009 Jan; 113(4):883-6. PubMed ID: 19036704
[TBL] [Abstract][Full Text] [Related]
8. ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-Jkappa/SHARP-mediated repression of notch target genes.
Salat D; Liefke R; Wiedenmann J; Borggrefe T; Oswald F
Mol Cell Biol; 2008 May; 28(10):3502-12. PubMed ID: 18332109
[TBL] [Abstract][Full Text] [Related]
9. Structure of the AML1-ETO NHR3-PKA(RIIα) complex and its contribution to AML1-ETO activity.
Corpora T; Roudaia L; Oo ZM; Chen W; Manuylova E; Cai X; Chen MJ; Cierpicki T; Speck NA; Bushweller JH
J Mol Biol; 2010 Sep; 402(3):560-77. PubMed ID: 20708017
[TBL] [Abstract][Full Text] [Related]
10. Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity.
Wichmann C; Becker Y; Chen-Wichmann L; Vogel V; Vojtkova A; Herglotz J; Moore S; Koch J; Lausen J; Mäntele W; Gohlke H; Grez M
Blood; 2010 Jul; 116(4):603-13. PubMed ID: 20430957
[TBL] [Abstract][Full Text] [Related]
11. Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.
Park S; Chen W; Cierpicki T; Tonelli M; Cai X; Speck NA; Bushweller JH
Blood; 2009 Apr; 113(15):3558-67. PubMed ID: 19204326
[TBL] [Abstract][Full Text] [Related]
12. Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera.
Huang G; Shigesada K; Wee HJ; Liu PP; Osato M; Ito Y
Blood; 2004 Apr; 103(8):3200-7. PubMed ID: 15070703
[TBL] [Abstract][Full Text] [Related]
13. Negative effects of GM-CSF signaling in a murine model of t(8;21)-induced leukemia.
Matsuura S; Yan M; Lo MC; Ahn EY; Weng S; Dangoor D; Matin M; Higashi T; Feng GS; Zhang DE
Blood; 2012 Mar; 119(13):3155-63. PubMed ID: 22223820
[TBL] [Abstract][Full Text] [Related]
14. Activated leukemic oncogenes AML1-ETO and c-kit: role in development of acute myeloid leukemia and current approaches for their inhibition.
Rulina AV; Spirin PV; Prassolov VS
Biochemistry (Mosc); 2010 Dec; 75(13):1650-66. PubMed ID: 21417999
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis of the t(8;21) translocation in acute myeloid leukaemia.
Ohki M
Semin Cancer Biol; 1993 Dec; 4(6):369-75. PubMed ID: 8142622
[TBL] [Abstract][Full Text] [Related]
16. Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis.
Ahn EY; Yan M; Malakhova OA; Lo MC; Boyapati A; Ommen HB; Hines R; Hokland P; Zhang DE
Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17103-8. PubMed ID: 18952841
[TBL] [Abstract][Full Text] [Related]
17. The AML1/ETO fusion protein activates transcription of BCL-2.
Klampfer L; Zhang J; Zelenetz AO; Uchida H; Nimer SD
Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14059-64. PubMed ID: 8943060
[TBL] [Abstract][Full Text] [Related]
18. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.
Yan M; Kanbe E; Peterson LF; Boyapati A; Miao Y; Wang Y; Chen IM; Chen Z; Rowley JD; Willman CL; Zhang DE
Nat Med; 2006 Aug; 12(8):945-9. PubMed ID: 16892037
[TBL] [Abstract][Full Text] [Related]
19. AML1-ETO needs a partner: new insights into the pathogenesis of t(8;21) leukemia.
Kuchenbauer F; Feuring-Buske M; Buske C
Cell Cycle; 2005 Dec; 4(12):1716-8. PubMed ID: 16294039
[TBL] [Abstract][Full Text] [Related]
20. Multi-sites cleavage of leukemogenic AML1-ETO fusion protein by caspase-3 and its contribution to increased apoptotic sensitivity.
Lu Y; Peng ZG; Yuan TT; Yin QQ; Xia L; Chen GQ
Leukemia; 2008 Feb; 22(2):378-86. PubMed ID: 17989718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
